

Anna Falanga

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4792752/publications.pdf>

Version: 2024-02-01

197
papers

16,790
citations

22153

59
h-index

15732

125
g-index

207
all docs

207
docs citations

207
times ranked

17062
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Widespread Arterial Thrombosis after ChAdOx1 nCov-19 Vaccination. Case Reports in Critical Care, 2022, 2022, 1-4. | 0.4 | 2 |
| 2 | Treatment Resistance Risk in Patients with Newly Diagnosed Multiple Myeloma Is Associated with Blood Hypercoagulability: The ROADMAP-MM Study. Hemato, 2022, 3, 188-203. | 0.6 | 1 |
| 3 | Cancer-associated venous thromboembolism. Nature Reviews Disease Primers, 2022, 8, 11. | 30.5 | 130 |
| 4 | Editorial: Role of the Platelet Phenomenon in Cardiovascular Diseases and Cancer. Frontiers in Cardiovascular Medicine, 2022, 9, 859770. | 2.4 | 0 |
| 5 | The COMPASS-COVID-19-ICU Study: Identification of Factors to Predict the Risk of Intubation and Mortality in Patients with Severe COVID-19. Hemato, 2022, 3, 204-218. | 0.6 | 0 |
| 6 | How well do European patients understand cancer-associated thrombosis? A patient survey. Cancer Treatment and Research Communications, 2022, 31, 100557. | 1.7 | 4 |
| 7 | Hemostatic system activation in breast cancer: Searching for new biomarkers for cancer risk prediction and outcomes. Thrombosis Research, 2022, 213, S46-S50. | 1.7 | 0 |
| 8 | Standardization of risk prediction model reporting in cancer-associated thrombosis: Communication from the ISTH-ASCC subcommittee on hemostasis and malignancy. Journal of Thrombosis and Haemostasis, 2022, 20, 1920-1927. | 3.8 | 3 |
| 9 | EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer. HemaSphere, 2022, 6, e750. | 2.7 | 29 |
| 10 | ISTH guidelines for antithrombotic treatment in COVID-19. Journal of Thrombosis and Haemostasis, 2022, 20, 2214-2225. | 3.8 | 100 |
| 11 | Thrombotic complications in patients with cancer: Advances in pathogenesis, prevention, and treatment—A report from ICTHIC 2021. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12744. | 2.3 | 4 |
| 12 | A microphysiological early metastatic niche on a chip reveals how heterotypic cell interactions and inhibition of integrin subunit α_3 impact breast cancer cell extravasation. Lab on a Chip, 2021, 21, 1061-1072. | 6.0 | 21 |
| 13 | Validation of the Role of Thrombin Generation Potential by a Fully Automated System in the Identification of Breast Cancer Patients at High Risk of Disease Recurrence. TH Open, 2021, 05, e56-e65. | 1.4 | 9 |
| 14 | Prevention and Management of Thrombosis in BCR/ABL-Negative Myeloproliferative Neoplasms. Hamostaseologie, 2021, 41, 048-057. | 1.9 | 12 |
| 15 | The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper. Thrombosis and Haemostasis, 2021, 121, 992-1007. | 3.4 | 21 |
| 16 | Management and Outcomes of Isolated Distal Deep Vein Thromboses: A Questionable Trend toward Long-Lasting Anticoagulation Treatment. Results from the START-Register. TH Open, 2021, 05, e239-e250. | 1.4 | 1 |
| 17 | Management of Cancer-Associated Thrombosis: Unmet Needs and Future Perspectives. TH Open, 2021, 05, e376-e386. | 1.4 | 18 |
| 18 | Hemostatic Biomarkers and Cancer Prognosis: Where Do We Stand?. Seminars in Thrombosis and Hemostasis, 2021, 47, 962-971. | 2.7 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Acquired Autoimmune Hemophilia Following SARS-CoV-2 Vaccines: Dual-Drug Effects on Blood Coagulation and the Scylla and Charybdis Phenomenon. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1555-1557. | 3.4 | 5 |
| 20 | Thrombosis in myeloproliferative neoplasms: A clinical and pathophysiological perspective. <i>Thrombosis Update</i> , 2021, 5, 100081. | 0.9 | 8 |
| 21 | Tissue Plasminogen Activator Levels and Risk of Breast Cancer in a Caseâ€“Cohort Study on Italian Women: Results from the Moli-sani Study. <i>Thrombosis and Haemostasis</i> , 2021, 121, 449-456. | 3.4 | 5 |
| 22 | Hemostatic Markers, Adamts-13 Profile and Anti-Sars-Cov-2 Antibody Levels in Patients with Immune Thrombotic Thrombocytopenic Purpura Receiving BNT162b2 Vaccination. <i>Blood</i> , 2021, 138, 1022-1022. | 1.4 | 1 |
| 23 | MPN and thrombosis was hard enough .â€“. now there's COVID-19 thrombosis too. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 710-717. | 2.5 | 2 |
| 24 | Evidence-Based Minireview: Are DOACs an alternative to vitamin K antagonists for treatment of venous thromboembolism in patients with MPN?. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 448-452. | 2.5 | 1 |
| 25 | Increased platelet thrombus formation under flow conditions in whole blood from polycythaemia vera patients. <i>Blood Transfusion</i> , 2021, , . | 0.4 | 1 |
| 26 | Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 496-520. | 1.6 | 971 |
| 27 | Hemostatic biomarkers in occult cancer and cancer risk prediction. <i>Thrombosis Research</i> , 2020, 191, S37-S42. | 1.7 | 15 |
| 28 | Preface to the Proceedings of the 10th International Conference on Thrombosis and Hemostasis Issues in Cancer, 2020. <i>Thrombosis Research</i> , 2020, 191, S1-S2. | 1.7 | 0 |
| 29 | Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1597-1628. | 3.4 | 131 |
| 30 | Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow-Up Survey. <i>Oncologist</i> , 2020, 25, e1091-e1097. | 3.7 | 10 |
| 31 | Thrombin generation predicts early recurrence in breast cancer patients. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2220-2231. | 3.8 | 17 |
| 32 | Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1004-1024. | 3.4 | 206 |
| 33 | Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 267-277. | 2.1 | 54 |
| 34 | Low levels of <sc>ADAMTS</sc>â€“13 with high <sc>anti-ADAMTS</sc>â€“13 antibodies during remission of immuneâ€“mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multiâ€“institutional study. <i>American Journal of Hematology</i> , 2020, 95, 953-959. | 4.1 | 14 |
| 35 | Anticoagulation in thrombocytopenic patients with hematological malignancy: A multinational clinical vignette-based experiment. <i>European Journal of Internal Medicine</i> , 2020, 77, 86-96. | 2.2 | 7 |
| 36 | Type and dose of heparin in Covidâ€“19: Reply. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2063-2064. | 3.8 | 19 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Laboratory haemostasis monitoring in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2058-2060. | 3.8 | 25 |
| 38 | COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2950-2973. | 2.8 | 2,392 |
| 39 | Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer. <i>Haematologica</i> , 2020, 105, 1704-1711. | 3.5 | 21 |
| 40 | The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 278-284. | 3.8 | 26 |
| 41 | Extensive Characterization of the Hemostatic Derangement Occurring in COVID-19 Patients Admitted to the Bergamo Hospital. <i>Blood</i> , 2020, 136, 36-36. | 1.4 | 1 |
| 42 | Thrombin Generation and D-Dimer Significantly Predict for Early Disease Progression and Mortality in Patients with Gastrointestinal Cancer. <i>Blood</i> , 2020, 136, 32-32. | 1.4 | 0 |
| 43 | Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper. <i>Blood Cancer Journal</i> , 2019, 9, 61. | 6.2 | 25 |
| 44 | Pathophysiology 1. Mechanisms of Thrombosis in Cancer Patients. <i>Cancer Treatment and Research</i> , 2019, 179, 11-36. | 0.5 | 56 |
| 45 | The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1772-1778. | 3.8 | 107 |
| 46 | 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Lancet Oncology</i> , The, 2019, 20, e566-e581. | 10.7 | 458 |
| 47 | Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update Summary. <i>Journal of Oncology Practice</i> , 2019, 15, 661-664. | 2.5 | 33 |
| 48 | Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1694-1706. | 3.8 | 30 |
| 49 | Treatment of venous thromboembolism with tinzaparin in oncological patients. <i>Minerva Medica</i> , 2019, 110, 251-258. | 0.9 | 6 |
| 50 | Activated prothrombin complex concentrate (FEIBA [®]) in acquired haemophilia A: a large multicentre Italian study – the FAIR Registry. <i>British Journal of Haematology</i> , 2019, 184, 853-855. | 2.5 | 24 |
| 51 | Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. <i>Hematological Oncology</i> , 2018, 36, 624-632. | 1.7 | 55 |
| 52 | A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 417-434. | 2.9 | 81 |
| 53 | Acute promyelocytic leukemia cell adhesion to vascular endothelium is reduced by heparins. <i>Annals of Hematology</i> , 2018, 97, 1555-1562. | 1.8 | 13 |
| 54 | APL Coagulopathy. , 2018, , 55-70. | | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Hemostatic biomarkers in cancer progression. <i>Thrombosis Research</i> , 2018, 164, S54-S61. | 1.7 | 43 |
| 56 | Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study. <i>Oncologist</i> , 2018, 23, 1372-1381. | 3.7 | 36 |
| 57 | Antithrombotic medication in cancer-associated thrombocytopenia: Current evidence and knowledge gaps. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 132, 76-88. | 4.4 | 17 |
| 58 | Two Missense Variants Detected in Breast Cancer Proband Preventing BRCA2-PALB2 Protein Interaction. <i>Frontiers in Oncology</i> , 2018, 8, 480. | 2.8 | 11 |
| 59 | Preface. <i>Thrombosis Research</i> , 2018, 164, S1-S2. | 1.7 | 0 |
| 60 | Risk of Venous Thromboembolism in Surgical Elderly Patients. , 2018, , 65-78. | | 0 |
| 61 | Italian intersociety consensus on DOAC use in internal medicine. <i>Internal and Emergency Medicine</i> , 2017, 12, 387-406. | 2.0 | 44 |
| 62 | Predicting APL lethal bleeding in the ATRA era. <i>Blood</i> , 2017, 129, 1739-1740. | 1.4 | 12 |
| 63 | Mechanisms and risk factors of thrombosis in cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 118, 79-83. | 4.4 | 183 |
| 64 | Heparins inhibit the endothelial pro-thrombotic features induced by tumor cells. <i>Thrombosis Research</i> , 2017, 157, 55-57. | 1.7 | 4 |
| 65 | Long Term Low Molecular Weight Heparin Anticoagulant Therapy Modulates Thrombin Generation and D-dimer in Patients with Cancer and Venous Thromboembolism. <i>Cancer Investigation</i> , 2017, 35, 490-499. | 1.3 | 13 |
| 66 | Platelet haemostatic properties in $\hat{1}^2$ -thalassaemia: the effect of blood transfusion. <i>Blood Transfusion</i> , 2017, 15, 413-421. | 0.4 | 8 |
| 67 | Managing reversal of direct oral anticoagulants in emergency situations. <i>Thrombosis and Haemostasis</i> , 2016, 116, 1003-1010. | 3.4 | 39 |
| 68 | The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE. <i>Thrombosis and Haemostasis</i> , 2016, 115, 1101-1108. | 3.4 | 24 |
| 69 | Preface. <i>Thrombosis Research</i> , 2016, 140, ix-x. | 1.7 | 0 |
| 70 | Molecular biomarkers of thrombosis in myeloproliferative neoplasms. <i>Thrombosis Research</i> , 2016, 140, S71-S75. | 1.7 | 28 |
| 71 | Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study. <i>Thrombosis Research</i> , 2016, 140, S55-S59. | 1.7 | 29 |
| 72 | Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 1254-1256.e4. | 1.2 | 9 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Haplotype analyses of the c.1027C>T and c.2167_2168delAT recurrent truncating mutations in the breast cancer-predisposing gene PALB2. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 121-129. | 2.5 | 11 |
| 74 | The International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) at the Peak of Adolescence “ 15 Years and Counting. <i>Thrombosis Research</i> , 2016, 140, S99-S102. | 1.7 | 0 |
| 75 | A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality. <i>Oncologist</i> , 2016, 21, 861-867. | 3.7 | 54 |
| 76 | Cancer Tissue Procoagulant Mechanisms and the Hypercoagulable State of Patients with Cancer. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 756-764. | 2.7 | 84 |
| 77 | The mechanisms of cancer-associated thrombosis. <i>Thrombosis Research</i> , 2015, 135, S8-S11. | 1.7 | 114 |
| 78 | Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. <i>Journal of Clinical Oncology</i> , 2015, 33, 654-656. | 1.6 | 911 |
| 79 | <i>FANCM</i> c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. <i>Human Molecular Genetics</i> , 2015, 24, 5345-5355. | 2.9 | 91 |
| 80 | Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Oncology Practice</i> , 2015, 11, e442-e444. | 2.5 | 115 |
| 81 | Eradication of acquired hemophilia associated with indolent non-Hodgkin lymphoma by a disease specific treatment. <i>Leukemia and Lymphoma</i> , 2015, 56, 3210-3212. | 1.3 | 2 |
| 82 | Evaluation of nucleated red blood cell count by Sysmex XE-2100 in patients with thalassaemia or sickle cell anaemia and in neonates. <i>Blood Transfusion</i> , 2015, 13, 588-94. | 0.4 | 7 |
| 83 | Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia. <i>American Journal of Hematology</i> , 2014, 89, 68-73. | 4.1 | 53 |
| 84 | The coagulopathy of cancer. <i>Current Opinion in Hematology</i> , 2014, 21, 423-429. | 2.5 | 74 |
| 85 | Thrombosis in Myeloproliferative Neoplasms. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 348-358. | 2.7 | 84 |
| 86 | PALB2 sequencing in Italian familial breast cancer cases reveals a high-risk mutation recurrent in the province of Bergamo. <i>Genetics in Medicine</i> , 2014, 16, 688-694. | 2.4 | 25 |
| 87 | ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera. <i>Thrombosis Research</i> , 2013, 132, 88-93. | 1.7 | 41 |
| 88 | Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2013, 31, 2189-2204. | 1.6 | 717 |
| 89 | Coagulation and cancer: biological and clinical aspects. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 223-233. | 3.8 | 377 |
| 90 | Mechanisms of thrombosis in cancer. <i>Thrombosis Research</i> , 2013, 131, S59-S62. | 1.7 | 94 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Tissue Factor Expression on Platelet Surface during Preparation and Storage of Platelet Concentrates. <i>Transfusion Medicine and Hemotherapy</i> , 2013, 40, 126-132. | 1.6 | 11 |
| 92 | Reply to T.H. Oo. <i>Journal of Clinical Oncology</i> , 2013, 31, 4381-4382. | 1.6 | 3 |
| 93 | Myeloproliferative neoplasms and thrombosis. <i>Blood</i> , 2013, 122, 2176-2184. | 1.4 | 303 |
| 94 | Circulating microparticles in children with sickle cell anemia: a heterogeneous procoagulant storm directed by hemolysis and fetal hemoglobin. <i>Haematologica</i> , 2013, 98, 995-997. | 3.5 | 7 |
| 95 | Platelet Cut-Off For Anticoagulant Therapy In Cancer Patients With Venous Thromboembolism and Thrombocytopenia: An Expert Opinion Based On RAND/UCLA Appropriateness Method (RAM). <i>Blood</i> , 2013, 122, 581-581. | 1.4 | 5 |
| 96 | Thrombosis and Cancer: Emerging Data for the Practicing Oncologist. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e337-e345. | 3.8 | 16 |
| 97 | Thrombosis and Cancer: Emerging Data for the Practicing Oncologist. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , e337-e345. | 3.8 | 9 |
| 98 | Characterization of the thrombin generation potential of leukemic and solid tumor cells by calibrated automated thrombography. <i>Haematologica</i> , 2012, 97, 1173-1180. | 3.5 | 44 |
| 99 | Venous thromboembolism in the hematologic malignancies. <i>Current Opinion in Oncology</i> , 2012, 24, 702-710. | 2.4 | 55 |
| 100 | Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. <i>Blood</i> , 2012, 119, 933-939. | 1.4 | 260 |
| 101 | Preface. <i>Thrombosis Research</i> , 2012, 129, ix. | 1.7 | 0 |
| 102 | Microparticles in tumor progression. <i>Thrombosis Research</i> , 2012, 129, S132-S136. | 1.7 | 50 |
| 103 | Prevention of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)1. <i>Thrombosis Research</i> , 2012, 129, e171-e176. | 1.7 | 46 |
| 104 | Anticancer treatment and thrombosis. <i>Thrombosis Research</i> , 2012, 129, 353-359. | 1.7 | 43 |
| 105 | Epidemiology, risk and outcomes of venous thromboembolism in cancer. <i>Hamostaseologie</i> , 2012, 32, 115-125. | 1.9 | 64 |
| 106 | Thrombotic disease in the myeloproliferative neoplasms. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 571-581. | 2.5 | 102 |
| 107 | Platelet-mediated proteolytic down regulation of the anticoagulant activity of protein S in individuals with haematological malignancies. <i>Thrombosis and Haemostasis</i> , 2012, 107, 468-476. | 3.4 | 17 |
| 108 | Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1297-1302. | 3.8 | 129 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Mechanisms of Thrombogenesis. , 2012, , 57-67. | | 2 |
| 110 | Thrombotic disease in the myeloproliferative neoplasms. Hematology American Society of Hematology Education Program, 2012, 2012, 571-81. | 2.5 | 48 |
| 111 | LMWH Bemiparin and ULMWH RO-14 Reduce the Endothelial Angiogenic Features Elicited by Leukemia, Lung Cancer, or Breast Cancer Cells. Cancer Investigation, 2011, 29, 153-161. | 1.3 | 24 |
| 112 | All trans-retinoic acid modulates the procoagulant activity of human breast cancer cells. Thrombosis Research, 2011, 128, 368-374. | 1.7 | 15 |
| 113 | Defining the Thrombotic Risk in Patients with Myeloproliferative Neoplasms. Scientific World Journal, The, 2011, 11, 1131-1137. | 2.1 | 23 |
| 114 | Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival. Patient Related Outcome Measures, 2011, 2, 175. | 1.2 | 15 |
| 115 | Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation.. Thrombosis and Haemostasis, 2011, 106, 868-876. | 3.4 | 158 |
| 116 | JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. Blood, 2011, 118, 2599-2601. | 1.4 | 61 |
| 117 | Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera. American Journal of Hematology, 2011, 86, 337-342. | 4.1 | 78 |
| 118 | PATHOGENESIS AND TREATMENT OF THROMBOHEMORRHAGIC DIATHESIS IN ACUTE PROMYELOCYTIC LEUKEMIA. Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e2011068. | 1.3 | 29 |
| 119 | Prospective study of hemostatic alterations in children with acute lymphoblastic leukemia. American Journal of Hematology, 2010, 85, 325-330. | 4.1 | 64 |
| 120 | Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms. Thrombosis and Haemostasis, 2010, 104, 151-156. | 3.4 | 51 |
| 121 | Treatment of thromboembolism in cancer patients. Expert Opinion on Pharmacotherapy, 2010, 11, 2049-2058. | 1.8 | 8 |
| 122 | Monitoring thrombin generation: Is addition of corn trypsin inhibitor needed?. Thrombosis and Haemostasis, 2009, 101, 1156-1162. | 3.4 | 83 |
| 123 | Coagulation in Hematological Malignancies. Cancer Investigation, 2009, 27, 7-16. | 1.3 | 1 |
| 124 | Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. Haematologica, 2009, 94, 911-918. | 3.5 | 121 |
| 125 | Treatment of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thrombosis Research, 2009, 124, e32-e40. | 1.7 | 21 |
| 126 | Procoagulant mechanisms in tumour cells. Best Practice and Research in Clinical Haematology, 2009, 22, 49-60. | 1.7 | 146 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Thrombosis associated with angiogenesis inhibitors. Best Practice and Research in Clinical Haematology, 2009, 22, 115-128. | 1.7 | 100 |
| 128 | Venous Thromboembolism in the Hematologic Malignancies. Journal of Clinical Oncology, 2009, 27, 4848-4857. | 1.6 | 179 |
| 129 | The Incidence and Risk of Venous Thromboembolism Associated With Cancer and Nonsurgical Cancer Treatment. Cancer Investigation, 2009, 27, 105-115. | 1.3 | 51 |
| 130 | Venous Thromboembolism Prophylaxis and Treatment in Cancer: A Consensus Statement of Major Guidelines Panels and Call to Action. Journal of Clinical Oncology, 2009, 27, 4919-4926. | 1.6 | 162 |
| 131 | Activation of Clotting Factors in Cancer. Cancer Treatment and Research, 2009, 148, 31-41. | 0.5 | 39 |
| 132 | Monitoring thrombin generation: is addition of corn trypsin inhibitor needed?. Thrombosis and Haemostasis, 2009, 101, 1156-62. | 3.4 | 23 |
| 133 | Hemostatic complications of angiogenesis inhibitors in cancer patients. American Journal of Hematology, 2008, 83, 862-870. | 4.1 | 62 |
| 134 | Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin. Thrombosis Research, 2008, 121, 637-645. | 1.7 | 80 |
| 135 | Hypercoagulability and Tissue Factor Gene Upregulation in Hematologic Malignancies. Seminars in Thrombosis and Hemostasis, 2008, 34, 204-210. | 2.7 | 59 |
| 136 | Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood, 2008, 112, 4061-4068. | 1.4 | 136 |
| 137 | Summary and Conclusions. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2007, 36, 212-214. | 0.3 | 4 |
| 138 | Heparin in Tumor Progression and Metastatic Dissemination. Seminars in Thrombosis and Hemostasis, 2007, 33, 688-694. | 2.7 | 53 |
| 139 | Leukocytosis, JAK2 ^{V617F} Mutation, and Hemostasis in Myeloproliferative Disorders. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2007, 36, 148-159. | 0.3 | 36 |
| 140 | Bleeding and thrombosis in acute leukemia: What does the future of therapy look like?. Thrombosis Research, 2007, 120, S99-S106. | 1.7 | 73 |
| 141 | Cancer, thrombosis and heparin-induced thrombocytopenia. Thrombosis Research, 2007, 120, S137-S140. | 1.7 | 53 |
| 142 | Management of Thrombohemorrhagic Syndromes (THS) in Hematologic Malignancies. Hematology American Society of Hematology Education Program, 2007, 2007, 165-171. | 2.5 | 51 |
| 143 | American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer. Journal of Clinical Oncology, 2007, 25, 5490-5505. | 1.6 | 875 |
| 144 | V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Experimental Hematology, 2007, 35, 702-711. | 0.4 | 169 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 145 | Overview of the Postulated Mechanisms Linking Cancer and Thrombosis. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2007, 36, 122-130. | 0.3 | 63 |
| 146 | Venous Thromboembolism and Cancer. , 2007, , 199-211. | | 0 |
| 147 | Blood oxidative status and selectins plasma levels in healthy donors receiving granulocyte-colony stimulating factor. Leukemia, 2006, 20, 1430-1434. | 7.2 | 15 |
| 148 | Cancer and Venous Thromboembolism. Seminars in Thrombosis and Hemostasis, 2006, 32, 694-699. | 2.7 | 43 |
| 149 | Anticoagulants and Cancer Survival. Seminars in Thrombosis and Hemostasis, 2006, 32, 810-813. | 2.7 | 17 |
| 150 | The extension of disease is associated to an increased risk of venous thromboembolism (VTE) in patients with gastrointestinal (GI) carcinoma. Thrombosis and Haemostasis, 2006, 95, 752-754. | 3.4 | 7 |
| 151 | Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties. Haematologica, 2006, 91, 207-14. | 3.5 | 31 |
| 152 | Effect of anticoagulant drugs in cancer. Current Opinion in Pulmonary Medicine, 2005, 11, 403-407. | 2.6 | 23 |
| 153 | Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. British Journal of Haematology, 2005, 129, 811-817. | 2.5 | 134 |
| 154 | Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Experimental Hematology, 2005, 33, 523-530. | 0.4 | 212 |
| 155 | Deep vein thrombosis in cancer: the scale of the problem and approaches to management. Annals of Oncology, 2005, 16, 696-701. | 1.2 | 132 |
| 156 | Thrombophilia in Cancer. Seminars in Thrombosis and Hemostasis, 2005, 31, 104-110. | 2.7 | 131 |
| 157 | Cancer and venous thromboembolism. Lancet Oncology, The, 2005, 6, 401-410. | 10.7 | 525 |
| 158 | Pathogenesis of Thrombosis in Essential Thrombocythemia and Polycythemia Vera: The Role of Neutrophils. Seminars in Hematology, 2005, 42, 239-247. | 3.4 | 86 |
| 159 | The predictive value of D-dimer measurement for cancer in patients with deep vein thrombosis. Haematologica, 2005, 90, 149. | 3.5 | 10 |
| 160 | The effect of anticoagulant drugs on cancer. Journal of Thrombosis and Haemostasis, 2004, 2, 1263-1265. | 3.8 | 26 |
| 161 | Venous thromboembolism in oncology. Eksperimentalnii Onkologii, 2004, 26, 11-4. | 0.1 | 1 |
| 162 | Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia, 2003, 17, 1636-1642. | 7.2 | 115 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia. Best Practice and Research in Clinical Haematology, 2003, 16, 463-482. | 1.7 | 65 |
| 164 | Biological and Clinical Aspects of Anticancer Effects of Antithrombotics. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2003, 33, 389-392. | 0.3 | 11 |
| 165 | All-Trans-Retinoic Acid and Bleeding/Thrombosis. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2003, 33, 19-21. | 0.3 | 18 |
| 166 | Thrombosis and malignancy: an underestimated problem. Haematologica, 2003, 88, 607-10. | 3.5 | 6 |
| 167 | All-trans retinoic acid modulates microvascular endothelial cell hemostatic properties. Haematologica, 2003, 88, 895-905. | 3.5 | 24 |
| 168 | Clotting mechanisms and cancer: implications in thrombus formation and tumor progression. Clinical Advances in Hematology and Oncology, 2003, 1, 673-8. | 0.3 | 75 |
| 169 | Effect of all-trans-Retinoic acid on the hypercoagulable state of patients with breast cancer. American Journal of Hematology, 2002, 70, 9-15. | 4.1 | 15 |
| 170 | Molecular Basis for the Relationship Between Thrombosis and Cancer. Thrombosis Research, 2001, 102, V215-V224. | 1.7 | 303 |
| 171 | Pathogenesis of Thrombosis in Patients with Malignancy. International Journal of Hematology, 2001, 73, 137-144. | 1.6 | 102 |
| 172 | Coagulopathy of Acute Promyelocytic Leukemia. Acta Haematologica, 2001, 106, 43-51. | 1.4 | 60 |
| 173 | Pathogenetic Mechanisms of Thrombosis in Malignancy. Acta Haematologica, 2001, 106, 18-24. | 1.4 | 85 |
| 174 | Disseminated Intravascular Coagulation in Acute Leukemia. Seminars in Thrombosis and Hemostasis, 2001, 27, 593-604. | 2.7 | 123 |
| 175 | Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood, 2000, 96, 4261-4266. | 1.4 | 259 |
| 176 | The Decanucleotide Insertion/Deletion Polymorphism in the Promoter Region of the Coagulation Factor VII Gene and the Risk of Familial Myocardial Infarction. Thrombosis Research, 2000, 98, 9-17. | 1.7 | 33 |
| 177 | Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood, 2000, 96, 4261-4266. | 1.4 | 8 |
| 178 | Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood, 2000, 96, 4261-6. | 1.4 | 77 |
| 179 | Pathophysiology of the Thrombophilic State in the Cancer Patient. Seminars in Thrombosis and Hemostasis, 1999, 25, 173-182. | 2.7 | 231 |
| 180 | Aspirin increases the bleeding side effects in essential thrombocythemia independent of the cyclooxygenase pathway: Role of the lipoxygenase pathway. , 1998, 57, 277-282. | | 32 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 181 | Mechanisms of Hypercoagulation in Malignancy and during Chemotherapy. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1998, 28, 50-60. | 0.3 | 31 |
| 182 | The Impact of All-trans-Retinoic Acid on the Coagulopathy of Acute Promyelocytic Leukemia. Blood, 1998, 91, 3093-3102. | 1.4 | 213 |
| 183 | The Impact of All-trans-Retinoic Acid on the Coagulopathy of Acute Promyelocytic Leukemia. Blood, 1998, 91, 3093-3102. | 1.4 | 2 |
| 184 | Proteolysis of von Willebrand factor is decreased in acute promyelocytic leukaemia by treatment with all-trans-retinoic acid. British Journal of Haematology, 1996, 92, 733-739. | 2.5 | 27 |
| 185 | All-trans RETINOIC ACID INCREASES ADHESION TO ENDOTHELIUM OF THE HUMAN PROMYELOCYTIC LEUKAEMIA CELL LINE NB4. British Journal of Haematology, 1996, 93, 360-366. | 2.5 | 113 |
| 186 | Hemostatic System Activation in Patients with Lupus Anticoagulant and Essential Thrombocythemia. Seminars in Thrombosis and Hemostasis, 1994, 20, 324-327. | 2.7 | 16 |
| 187 | Inefficacy of intravenous immunoglobulin in patients with low-risk thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. American Journal of Hematology, 1992, 41, 165-169. | 4.1 | 38 |
| 188 | Inhibition of cancer procoagulant by peptidyl diazomethyl ketones and peptidyl sulfonium salts. Thrombosis Research, 1989, 54, 389-398. | 1.7 | 15 |
| 189 | Human breast and colon carcinomas express cysteine proteinase activities with pro-aggregating and pro-coagulant properties. International Journal of Cancer, 1988, 42, 554-557. | 5.1 | 46 |
| 190 | Procoagulant activity of mouse transformed cells: Different expression in freshly isolated or cultured cells. In Vitro Cellular & Developmental Biology, 1988, 24, 1154-1158. | 1.0 | 9 |
| 191 | INTRAVENOUS GAMMAGLOBULIN, ANTIPHOSPHOLIPID ANTIBODIES, AND THROMBOCYTOPENIA. Lancet, The, 1988, 332, 969. | 13.7 | 9 |
| 192 | Several murine metastasizing tumors possess a cysteine proteinase with cancer procoagulant characteristics. International Journal of Cancer, 1987, 39, 774-777. | 5.1 | 21 |
| 193 | Vitamin K-Dependent Procoagulant in Cancer Cells: A Potential Target for the Antimetastatic Effect of Warfarin?. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1986, 16, 288-294. | 0.3 | 2 |
| 194 | Comparison of properties of cancer procoagulant and human amnion-chorion procoagulant. BBA - Proteins and Proteomics, 1985, 831, 161-165. | 2.1 | 19 |
| 195 | Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry, 1985, 24, 5558-5567. | 2.5 | 217 |
| 196 | ASPIRIN INHIBITS PLATELET AGGREGATION BUT NOT BECAUSE IT PREVENTS THROMBOXANE SYNTHESIS. Lancet, The, 1982, 320, 775. | 13.7 | 8 |
| 197 | Fibrinolytic Proteins and Factor XIII as Predictors of Thrombotic and Hemorrhagic Complications in Hospitalized COVID-19 Patients. Frontiers in Cardiovascular Medicine, 0, 9, . | 2.4 | 6 |